Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL (Q56995760)
Jump to navigation
Jump to search
article by Simona Soverini et al published March 2007 in Lancet Oncology Commission
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL |
article by Simona Soverini et al published March 2007 in Lancet Oncology Commission |
Statements
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL (English)
0 references
March 2007
0 references
8
0 references
3
0 references
273-4
0 references